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Abstract 
 
Economic analysts are increasingly likely to rely on systematic reviews and meta-analyses of 
health state utility values to inform the parameter inputs of decision-analytic modelling based 
economic evaluations. Beyond the context of economic evaluation, evidence from systematic 
reviews and meta-analyses of health state utility values can be used to inform broader health 
policy decisions. This paper provides practical guidance on how to conduct a systematic 
review and meta-analysis of health state utility values. The paper outlines a number of stages 
in conducting a systematic review, including identifying the appropriate evidence, study 
selection, data extraction and presentation, and quality and relevance assessment. The paper 
outlines three broad approaches that can be used to synthesise multiple estimates of health 
utilities for a given health state or condition, namely fixed-effect meta-analysis, random-
effects meta-analysis, and mixed-effects meta-regression. Each approach is illustrated by a 
synthesis of utility values for a hypothetical decision problem, and software code is provided. 
The paper highlights a number of methodological issues pertinent to the conduct of meta-
analysis or meta-regression. These include the importance of limiting synthesis to 
‘comparable’ utility estimates, e.g. those derived using common utility measurement 
approaches and sources of valuation; reliance on limited or poorly reported published data in 
primary utility assessment studies; the use of aggregate outcomes within analyses; 
approaches to generating measures of uncertainty; handling of median utility values; 
challenges surrounding the disentanglement of utility estimates collected serially within the 
context of prospective observational studies or prospective randomised trials; challenges 
surrounding the disentanglement of intervention effects; and approaches to measuring model 
validity. Areas of methodological debate and avenues for future research are highlighted. 
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Key Points for Decision Makers 
 
 The process of systematically reviewing health state utility values should involve a 
number of formal stages, including identifying the appropriate evidence, study selection, 
data extraction and presentation, and quality and relevance assessment. 
 When there are multiple estimates of health utilities for a given health state, fixed-effect 
meta-analysis, random-effects meta-analysis and mixed-effects meta-regression are 
alternative approaches for pooling values collected across a number of studies. 
 There are a number of methodological issues pertinent to the conduct of meta-analysis or 
meta-regression, including for example the importance of limiting synthesis to utility 
estimates derived using comparable methods and the challenges raised by limited or 
poorly reported data in primary utility assessment studies. 
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1. Introduction 
 
Cost-utility analysis remains the preferred form of economic evaluation for health technology 
assessment (HTA), pricing and reimbursement authorities in several countries, including the 
Pharmaceutical Benefits Advisory Committee (PBAC) in Australia [1], the Canadian Agency 
for Drugs and Technologies in Health (CADTH) in Canada [2], the Haute Autorité de Santé 
(HAS) in France [3], the College voor zorgverzekeringen (CVZ) in the Netherlands [4], the 
CatSalut in  Spain (Catalonia) [5],  the National Institute of Health and Care Excellence 
(NICE) in England and Wales [6], and the Scottish Medicines Consortium (SMC) in Scotland 
[7]. The results of cost-utility analyses are commonly expressed in terms of incremental cost 
per quality-adjusted life year (QALY) gained. In order to generate QALY estimates, 
preference-based health-related quality of life weights, commonly referred to as health state 
utility values, are combined with data on length of time in the health states of interest. 
Notably, utility values reflect people’s preferences or social judgements about the relative 
worth of alternative health states. They therefore move beyond a narrow biomedical 
perspective on health outcomes measurement towards an extra-welfarist perspective that can 
inform allocative decision-making. 
     Health economists apply a number of approaches for estimating health state utility values. 
These include direct valuation methods, such as the standard gamble (SG), time trade-off 
(TTO) and visual analogue scale (VAS); multi-attribute health status classification systems 
with preference scores, such as the EQ-5D [8], Health Utilities Index (HUI) [9], or SF-6D 
[10]; mapping from non-preference-based measures onto generic preference-based measures 
of health; development of preference-based measures derived from existing non-preference-
based measures; and development of new preference-based measures encompassing de novo 
descriptive systems and utility algorithms [11]. In a single study economic evaluation, for 
example a within-trial economic evaluation, alternative approaches for estimating health state 
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utility values can be prospectively incorporated into the study design. However, single study 
economic evaluations often present methodological challenges to the optimal collection of 
health state utility values as a result of, for example, the timing and frequency of health utility 
assessments and the heterogeneity of the study sample [12]. Moreover, it remains relatively 
rare that a single study economic evaluation will generate all the data required to inform a 
policy decision [13]. In the context of decision-analytic modelling based economic 
evaluations, analysts generally lack the time and resources to estimate primary utility values 
for all health states of interest. There are several circumstances therefore where analysts will 
resort to reviews of external evidence on health state utility values. 
     A number of structured or systematic reviews of health state utility values have been 
reported in the literature, the results of which have acted as data inputs into economic 
evaluations. Early seminal research by Tengs and Wallace identified 1,000 original health 
utility values in 154 studies [14], whilst Bell and colleagues identified 949 health utility 
values in 228 studies [15].  More recently, systematic reviews of utility values have been 
reported for a number of specific health states or population groups, for example liver disease 
[16], neuropathic pain [17], Alzheimer’s disease [18], unipolar depression [19], colorectal 
cancer [20], HIV/AIDS [21], breast cancer [22], type II diabetes [23], surgical site infection 
[24], Crohn’s disease and ulcerative colitis [25], Chronic Obstructive Pulmonary Disease 
[26], and childhood populations [27]. Methods guidance by some HTA agencies that 
recommend formal systematic reviews of parameter values for decision-analytic modelling 
based economic evaluations is likely to increase the number of systematic reviews of health 
state utility values undertaken [2, 3, 6]. Beyond the context of economic evaluation, evidence 
from systematic reviews of health state utility values can be used to inform estimates of 
health burden of disease [28]. 
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     There is also growing interest in meta-analytic methods that pool health state utility values 
collected across a number of studies. Although still relatively rare, these methods generate 
more precise estimates of the measure of interest, and estimates of uncertainty surrounding 
those values. Recourse to published meta-analyses of health state utility values should reduce 
the burden on cost-effectiveness modellers seeking a common source of values for economic 
evaluations across a clinical area or targeting a specific population group [29].  
     Building on previous guidance documents [30-32], the purpose of this paper is to provide 
a practical guide on methods for conducting a systematic review and meta-analysis of health 
state utility values. The focus is on describing within a single document the possible stages 
that should be followed in the systematic review and meta-analysis processes in order to 
enhance transparency, consistency and robustness of methods across studies that synthesise 
health state utility values. 
 
2. Systematic review methods 
 
The process of systematically reviewing health state utility values should involve a number of 
formal stages, including identifying the appropriate evidence, study selection, data extraction 
and presentation, and quality and relevance assessment. Readers are also referred to 
methodological guidance on the iterative review processes to be followed that has been 
published elsewhere [30-32]. The general principles that should apply to a well conducted 
systematic review of health state utility values are that: (i) advice is sought at the outset from 
an information specialist; (ii) methods are pre-specified in a dated and version-controlled 
protocol with clearly stated objectives, search terms, literature databases and other sources, 
inclusion/exclusion criteria, study selection methods, recording of reasons for exclusion, 
methods for dealing with discrepancies, data extraction templates and planned methods of 
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synthesis, registered with the Prospective Register of Systematic Reviews (PROSPERO); (iii) 
approval from an ethics committee or written informed consent are sought if individual-level 
data are accessed; and (iv) the systematic review is reported in accordance with the preferred 
reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [33]. The 
work of searching for and reviewing health state utility values is a specialist task that requires 
at least some training in economics methods.    
 
2.1 Identification of evidence 
 
Development of a search strategy for a systematic review of health state utility values is 
likely to require extensive piloting, and an assessment of the appropriate balance to be struck 
between increased sensitivity on the one hand and potential additional yield on the other. The 
search strategies of published reviews have relied heavily on the development of bespoke 
combinations of free-text direct valuation method terms, such as ‘standard gamble’ or ‘time 
trade-off’ or indirect valuation method terms, such as ‘EQ-5D’ or ‘SF-6D’ or ‘AQL-5D’, 
combined with relevant terms for the health states or population groups of interest. Particular 
attention is required to ensure that spelling variants (for example, ‘EQ-5D’ and ‘EQ 5D’), 
abbreviations (for example, ‘Child Health Utility 9 Dimension’ and ‘CHU-9D’) and 
synonyms (for example, ‘child’ and ‘kid’ and ‘youth’) are fully captured by the search 
strategy. The thesauri of major search engines such as Medline (MeSH) and Embase 
(EMTREE) do not provide granulated thesauri terms for common direct valuation methods, 
such as ‘standard gamble’, or common multi-attribute health status classification systems 
with preference scores, such as ‘EQ-5D’ [31]. The focus therefore is largely on identifying 
the appropriate combination of free text search terms.  
     Searches of health state utility values have commonly targeted major search engines, such 
as PubMed, Embase and EconLit. Methods specialist databases, such as the NHS Economic 
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Evaluation Database (NHS EED) [34] and the Cost-effectiveness Analysis Registry [35] are 
other potential sources of information. A further potential source of health state utility values 
is topic specialist or field databases. For example, a recent systematic review of childhood 
health utilities found that 15 of the 272 eligible studies were only identified through a topic 
specialist database, namely the Paediatric Economic Database Evaluation (PEDE) Project 
[27]. Supplementary search strategies include manual reference searching of bibliographies, 
contacts with experts in the field, citation searching and author searching. A further approach 
to identifying relevant utility values, which has not been widely applied, is to conduct 
targeted condition-specific searches of databases of randomised controlled trials (e.g. 
www.clinicaltrials.gov) and submissions to HTA agencies in order to identify studies that 
included utility measures as secondary outcomes. 
     A detailed example of a search strategy developed for the purposes of a systematic review 
of health state utility values is provided in Appendix A for illustrative purposes. 
 
2.2 Study selection 
 
The stages involved in selecting studies for inclusion in a systematic review of health state 
utility values are broadly analogous with those followed for systematic reviews of clinical 
effects, and can be broadly summarised as: (i) examining titles and abstracts to remove 
obviously irrelevant reports; (ii) retrieving full texts of potentially relevant reports; (iii) 
linking together multiple reports of the same study; (iv) examining full-text reports for 
compliance of studies with study eligibility criteria; (v) corresponding with study authors, 
where appropriate, to clarify study eligibility; and (vi) making final decisions on study 
inclusion before proceeding to data extraction and assessment [36]. It is recommended that 
assessments of study eligibility are conducted by at least two people, independently, with 
disagreements resolved by consensus or the involvement of a third reviewer. There are, in 
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addition, distinctive features of systematic reviews of health state utility values that merit 
particular attention when selecting studies. Utility values may be estimated in the context of a 
number of alternative study designs, including stand-alone preference elicitation studies, 
randomised controlled trials and various forms of economic evaluation. In the context of 
some study designs, for example decision-analytic modelling based economic evaluations, it 
may not be clear at the title and abstract stage whether the authors conducted primary 
research to estimate utility values or relied purely on secondary data. It may therefore be 
advisable to be inclusive at the screening stage(s) despite the increased workload likely to be 
entailed. In addition, justification should be provided for the inclusion of values derived from 
visual analogue scales that arguably lack a theoretical basis for QALY construction [37].  
 
2.3 Data extraction and presentation 
 
Following the selection of studies for inclusion in a systematic review, data on each study are 
usually extracted and entered onto a pre-piloted proforma. This process aids the narrative 
presentation of results, but has other benefits, including providing a final filter for identifying 
candidate studies that don’t meet the inclusion criteria of the review, and identifying data that 
may be required to modify health state utility values for application in a particular decision 
model [31]. Good practice guidance for systematic reviews suggests that the data extraction 
process should be conducted by two independent researchers, followed by a reconciliation 
process [36]. Available proformas from published reviews have varied in the volume and 
breath of information that is extracted from individual reports. The type of data extracted 
should ultimately be guided by the planned presentation of results and the planned analyses. 
The proforma applied within the systematic review of childhood health utilities is provided in 
Appendix B for illustrative purposes. 
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     It is preferable to extract alternative descriptive statistics for utility values (for example, 
means, standard deviations, medians, inter-quartile ranges) where these are available so that 
analysts can select the preferred statistics for their applications, or transform the data where 
required. If the study reports utility values for several populations, or sub-groups within one 
study population, it is preferable to also extract values for each group, thereby enhancing 
potential applications by analysts. 
 
2.4 Quality and relevance assessment 
 
Critical assessments of the quality of conduct and reporting of contributing studies are 
important, but constrained by the absence of widely-accepted tools. The CONSORT [38], 
STROBE [39] and CHEERS [40] statements include salient features for studies that generate 
utility values within the context of randomised controlled trials, observational studies and 
single study economic evaluations, respectively. However, those features relate mainly to the 
underpinning vehicles for data collection rather than the characteristics of health utility 
assessments. Cooper and colleagues have developed a ranking system for studies that derive 
health state utility values, ranging from direct utility assessments to Delphi panels and expert 
opinion [41]. More recently, Papaioannou and colleagues have described key criteria to 
consider in the utility assessment process, for example, respondent selection and recruitment, 
response rates to the instrument used, and levels of missing data and how they were dealt 
with [31]. Other relevant quality assessment criteria have been published [12, 32]. A 
particular feature of relevance when assessing the quality of contributing studies is their face 
validity or empirical validity, for example, whether they generate utility values that vary in an 
expected direction by level of severity for a specific condition [42]. In the absence of generic 
tools that encompass all potentially relevant features, it is incumbent on those involved in the 
review process to describe the quality of contributing studies in holistic terms, drawing where 
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necessary upon the relevant features of multiple checklists. If the systematic review is to be 
used to inform a pre-specified policy decision, a final stage in the review process should 
involve a separate assessment of the relevance of contributing studies to the requirements of 
the local agency considering the evidence [31]. This might include, for example, an 
assessment of whether contributing studies applied the agency’s preferred utility measure or 
derived values from the preferred population group. 
 
3. Meta-analysis and meta-regression of utility values 
 
When there are multiple estimates of health utilities for a given health state or condition, and 
if they are sufficiently homogenous, the estimates can be synthesised to provide a pooled 
estimate of the utility value, which can then be used to populate decision models in economic 
evaluation or inform broader policy questions [43]. A conservative approach to the inclusion 
of studies in such a synthesis is advised, bearing in mind the potential use of derived 
estimates to inform health economic models addressing specific decision problems in specific 
clinical areas. Health states for different diseases or conditions may share characteristics (e.g. 
loss of mobility), but have potentially radically different health-related quality of life 
consequences. In such cases, pooled utility values are unlikely to be appropriate. It may be 
possible to allow for exceptions where the populations or conditions are broadly similar, or it 
can be argued on clinical grounds that a systematic relationship exists between states so that 
their utilities can be jointly estimated allowing for a parameter that defines this systematic 
relationship. In such cases, pooling of utility values may be appropriate. However, a strong 
justification should be provided for doing so, and the impact of more restrictive assumptions 
on utility values should be presented alongside the broader estimates if at all possible. 
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     This section introduces three broad approaches that have been employed in the literature 
to synthesise comparable utility values: (i) fixed-effect meta-analysis; (ii) random-effects 
meta-analysis; and (iii) mixed-effects meta-regression. Each approach is illustrated by a 
synthesis of utility values for a hypothetical decision problem evaluating a new oncology 
drug that improves survival of paediatric cancer patients across several types of malignancies. 
CADTH is assumed to be the decision-maker. CADHT accepts both the HUI2 and HUI3 as 
preference-based multi-attribute utility measures for their reference case despite their 
differing attributes [2]. It is assumed that CADHT only accepts HUI2 and HUI3 utility values 
that reflect preferences of the Canadian population over health states. In the absence of any 
formal guidance by CADTH, utilities measured by different respondent types (e.g. self vs. 
proxies), administration modes (e.g. self vs. interviewer-administered) and in different years 
are assumed to be comparable for illustrative purposes.  The STATA and R codes used for 
the alternative approaches to synthesis are provided in Table 1. In addition, the reader is 
referred to Table 2, which summarises the characteristics of 19 studies identified by a 
structured review as having synthesised utility values, and which therefore provide a broader 
context to the methods that are described [16, 17, 19-22, 27, 44-55].  
 
3.1 Fixed-effect meta-analysis 
 
Fixed-effect meta-analysis assumes that utility values are drawn from the same underlying 
population and that variation is due purely to random error [56]. Figure 1 displays the result 
of a fixed-effect meta-analysis of 22 mean HUI2 and HUI3 utilities for paediatric cancer 
survivors, valued using Canadian tariffs, using data from Kwon and colleagues [27]. The 
exact STATA command using the ‘metan’ package and R command using the ‘metafor’ 
package is outlined in Table 1. By default, STATA uses inverse-variance weighted fixed-
effect meta-analysis. The fixed-effect estimate of mean HUI2/HUI3 utility scores for 
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paediatric cancer survivors is 0.93 (95% confidence interval: [0.927, 0.936]). There were 16 
utility scores published after 2000 and 6 in 2000 or earlier. Although utility scores across 
different years of publication are seen as comparable in this decision context, separate meta-
analyses enable the comparability assumption by year to be tested visually. Heterogeneity 
between the two groups is statistically insignificant (P=0.739) and both groups have a fixed-
effect estimate of 0.93. STATA presents Cochran’s Q statistics [57] and degrees of freedom 
for test of heterogeneity, as well as an 𝐼2 statistic where a large 𝐼2 statistic suggests that the 
level of heterogeneity not attributable to random error is large [58]. From the STATA output 
we conclude that there is significant variability between individual mean utilities overall 
(Q=316.97; P<0.001; 𝐼2=93.4%) and that there is greater variability between mean utilities 
published after 2000 (Q=309.48; P<0.001; 𝐼2=95.2%) than those published in 2000 or earlier 
(Q=7.38; P=0.194; 𝐼2=32.2%). 
 
3.2 Random-effects meta-analysis 
 
Random-effects meta-analysis relaxes the strong assumption that variation between samples 
and studies is due solely to random error around the true underlying value. The latter is now 
assumed to vary across samples and studies. Figure 2 displays the results of a random-effects 
meta-analysis on the same 22 mean HUI2 and HUI3 utilities for paediatric cancer survivors, 
this time grouped by HUI2 or HUI3. STATA uses the DerSimonian and Laird method by 
default [59] and each mean utility value is weighted by the inverse of variance. The 𝜏2 
statistic (reported in non-graph STATA output: 𝜏2=0.0018 for overall; 𝜏2=0.0049 for HUI3; 
𝜏2=0.009 for HUI2) estimates the level of between-study variation in underlying utility 
values. When grouped by HUI2 or HUI3, the 𝐼2 statistics suggest significant heterogeneity 
between samples in both groups (𝐼2=95.9% for HUI3; 𝐼2=89.1% for HUI2).  
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     Random-effects estimates of mean HUI2 utility values are larger than those of mean HUI3 
utility values under both fixed-effect and random-effects meta-analyses (0.92 vs. 0.86 for 
random-effects and 0.94 vs. 0.90 for fixed-effect). Whether this difference is statistically 
significant, controlling for other covariates, can be investigated using the meta-regression 
approach described below. For now, under the assumption in this decision context that HUI2 
and HUI3 scores are comparable, the relevant result from Figure 2 is the random-effects 
estimate of a mean utility value of 0.91 (95% confidence interval, [0.89, 0.93]) for paediatric 
cancer survivors, combined across HUI2 and HUI3.   
     Random-effects models can be used to generate ‘mean’ or ‘predictive’ estimates [60, 61]. 
The former represents the estimated pooled value, whereas the latter represents what might be 
expected for a new study or population. As seen from Figure 2, the predictive interval [0.82, 
1.00] is wider than the confidence interval [0.89, 0.93] for the overall mean estimate (while 
the predictive interval for HUI3 [0.67, 1.06] crosses the feasible range for utility score), 
reflecting the additional uncertainty from study/population heterogeneity. Deciding which of 
these two estimates is relevant depends on the use to which the estimate is to be put. 
Therefore, studies should preferably report both mean and predictive estimates.  
 
3.3 Mixed-effects meta-regression     
 
Meta-regression is an augmentation of fixed-effect or random-effects meta-analysis with 
covariates that can partly explain the heterogeneity between samples and studies. Meta-
regression with random-effects components is known as mixed-effects meta-regression since 
heterogeneity is accounted for by a mixture of random-effects and covariates. The mixed-
effects approach typically adopts a hierarchical linear structure as follows:  
𝑈𝑖𝑗𝑘 = 𝛽0 +∑𝛽𝑙
𝑙
𝑥𝑙𝑖𝑗𝑘 + 𝛾𝑖 + 𝜃𝑖𝑗 + 𝜀𝑖𝑗𝑘 
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where 𝑈𝑖𝑗𝑘 is the (weighted) mean of the k
th utility of the jth group (defined by combination of 
covariates) of study i, 𝑥𝑙𝑖𝑗𝑘 the covariates, 𝛾𝑖 the random-effects component of study i, 𝜃𝑖𝑗 the 
random-effects component of jth group of study i, and 𝜀𝑖𝑗𝑘 the random error. 𝛾𝑖, 𝜃𝑖𝑗, and 𝜀𝑖𝑗𝑘 
are residual variations unexplained by the covariates attributed to different levels within a 
multilevel structure [55, 62]. The mean utilities are typically weighted by the inverse of 
variance and clustered by group and study. The study-specific random effects capture the 
unobservable characteristics of the study (e.g., method of participant recruitment). The 
studies can also be weighted by their relative ‘importance’, proxied by total number of 
respondents [21, 27] or total variance (i.e. the sum of all standard errors of mean utilities) 
[20]. 
     Table 3 shows the results of a mixed-effects meta-regression using the same 22 mean 
HUI2 and HUI3 utility values for paediatric cancer survivors described above. The 
explanatory variables all take a binary form, including for the valuation method (reference 
HUI3 vs. HUI2), respondent type (reference self-response vs. proxy-response), 
administration mode (reference self-administered vs. interview-administered) and year of 
publication (reference after 2000 vs. 2000 or earlier). 
     The constant term in Table 3 suggests that the mean utility estimate for the reference case 
(i.e. mean HUI3 utility value for paediatric cancer survivors measured  using child responses 
through a self-administered questionnaire) is 0.870 (95% confidence interval: [0.786, 0.953]). 
The weighted average (using the inverse of prediction standard error as weights) of the mean 
utilities predicted by the model is 0.937 (95% confidence interval: [0.905, 0.969]). This 
estimate is higher than the fixed-effect estimate of 0.93 and the random-effects estimate of 
0.91.  
     The advantage of the meta-regression prediction is that it accounts for the statistically 
significant effects exerted by covariates (in this case, administration mode and year of 
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publication) not considered in fixed-effect and random-effects meta-analyses. Another 
advantage is that it allows examination of comparability assumptions, which cannot be done 
accurately using meta-analysis approaches. In fact, relying on the latter approaches could 
result in misleading conclusions. For example, Figure 1 suggests that year of publication 
accounts for an insignificant amount of heterogeneity between mean utilities. Table 3, by 
contrast, suggests that year of publication exerts a statistically significant effect (coefficient: -
0.115; 95% confidence interval [-0.194, -0.036], suggesting earlier published utilities are on 
average lower than later utilities) once other covariates are held fixed. This questions the 
initial assumption of treating utility estimates across disparate publication years as 
comparable. The analyst may therefore, in this decision context, consider including only 
recently published estimates in the decision model. Another example is the effect of valuation 
method. Figure 2 suggests that HUI2 utilities are significantly higher than HUI3 utilities 
under both fixed-effect and random-effects approaches. By contrast, although the direction of 
coefficient on HUI3 vs. HUI2 in Table 2 (0.043) supports this finding, the coefficient is 
statistically insignificant (P=0.068) once other covariates are held fixed. This supports the 
initial assumption that HUI2 and HUI3 can be treated as comparable measures for paediatric 
cancer survivors.  
     It should be noted that the mixed-effect meta-regression model in Table 3 tests four 
hypotheses simultaneously. This could result in type I errors (false-positives) where 
significant findings are driven by natural variation across multiple subgroups rather than non-
random effects of the explanatory variables [63]. This problem is particularly acute in meta-
regressions where there is significant between-study and between-group heterogeneity [64]. 
Bonferroni correction [65] is a simple but conservative way to address this issue by lowering 
the nominal significance level. If the significance level is 1 − 𝛼 then only the results with P-
values less than 𝛼/𝑘 where 𝑘 is the number of tests are interpreted as significant. Hence, with 
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𝛼 = 0.05 and 𝑘 = 4, the relevant P-value is 0.0125. Even so, in our example, both 
administration mode (P<0.001) and year of publication (P=0.004) are still associated with 
significant effects on utility values.   
 
4. Methodological considerations for meta-analysis and meta-regression  
 
Although meta-analysis and meta-regression improve our estimates of health utility values 
for a given health state or condition by making use of relevant sources of information across 
multiple studies and samples, analysts should be acquainted with several methodological 
considerations and limitations associated with their application.  
 
4.1 Selection of comparable utilities for synthesis  
 
It is important to limit synthesis to ‘comparable’ utility estimates, even in meta-regression 
where confounding factors are controlled for. In the examples above, for instance, utilities 
valued using different country-specific tariffs are not deemed comparable while HUI2 and 
HUI3 utilities (derived using Canadian tariffs) are deemed comparable. There is no fixed rule 
determining the bounds of comparability. Ideally, the acceptable level of comparability 
between health states (e.g. utility estimates for survivors of different types of cancer) should 
be defined by the decision problem and health states populating the decision model, while the 
acceptable level of comparability for methodological factors should ideally be guided by the 
decision-making body (e.g. the preferred utility measurement approach and source of 
valuation).   
     It is often unclear whether or not multiple utility estimates are reasonably comparable, 
especially regarding methodological factors such as respondent type, administration mode 
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and closely-related valuation methods (e.g. HUI2 vs. HUI3). A potential approach is to 
conduct a meta-regression as in Section 3.3 to identify methodological factors that exert 
statically significant effects on utility estimates. Analysts can then either: (i) use the predicted 
values of the meta-regression model that accounts for the independent effects; or (ii) conduct 
separate meta-analyses for sub-groups defined by the significant methodological factors. In 
addition, published meta-regression studies often explore statistical significance of clinical 
and methodological factors in meta-regression models [16, 17, 20-22, 27, 46, 47, 50, 52-55]; 
their results could hence serve as a guide on selecting a preliminary set of covariates for 
regression. However, caution is required when interpreting previous meta-regression results 
since it is unclear whether they are generalisable to different contexts, while statistically 
significant coefficients may be due to ecological fallacy (see Section 4.3), small sample sizes 
or multiple comparisons. Selection of covariates could also be informed by Akaike’s 
information criterion for nested models [49]. 
 
4.2 Insufficient information from published studies 
 
One major limitation of secondary evidence synthesis is its reliance on limited or poorly 
reported published data in primary utility assessment studies. The analyst’s response in this 
circumstance should depend on the nature of insufficient information. 
 
4.2.1 Insufficient information on health states 
Reporting of clinical details within utility assessments may be poor or idiosyncratic, resulting 
in non-uniform categorisation of health states across studies. This risks synthesising 
information on qualitatively different health states. Analysts should refer to external 
guidelines and epidemiological data to either clarify or re-classify health states to obtain 
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internal comparability with other samples. For example, Tengs and Lin [21] and Tran and 
colleagues [54] found that most but not all primary utility studies in the HIV/AIDS context 
classified HIV/AIDS stages as asymptomatic HIV, symptomatic HIV, and AIDS. Those that 
did not only reported CD4 counts and specific HIV/AIDS symptoms. Therefore, both meta-
analyses utilise epidemiological data to impute HIV/AIDS stage from CD4 counts and/or 
specific symptoms. Other commonly missing clinical details include disease severity, 
treatment regime for chronic diseases and time since diagnosis and intervention, as well as 
demographic factors such as age and gender.  
 
4.2.2 Insufficient information on methodological factors 
Paucity of information is also often a feature for methodological factors. Analysts should pay 
close attention to the description of study features in primary studies to extract information 
on, for example, administration mode and respondent type since these are often not explicitly 
stated. Moreover, primary studies may use and report several multi-attribute utility measures, 
all of which can potentially be acceptable in the decision context, but not detail which of the 
measures have psychometric properties best suited to the given health state or condition. 
Another component of commonly missing information relates to the population and valuation 
method by which tariffs for preference-based multi-attribute utility measures are derived. 
Primary studies frequently only provide a reference to the tariff valuation study, leaving the 
analyst to chase the reference to obtain relevant details. 
 
4.2.3 Synthesis of samples with insufficient information 
The analyst may face a trade-off on whether to include samples lacking in clinical or 
methodological details. Inclusion risks synthesis of potentially incomparable estimates whilst 
exclusion limits the sample size. Again, the most reasonable approach would depend on the 
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decision problem and context. If the decision model requires utility estimates for a specific 
level of disease severity, then samples with ambiguous severity descriptions should be 
excluded. If the decision-making body does not have a preferred respondent type or 
administration mode, including samples without clear description of these factors may be 
acceptable. For some health states (e.g., childhood health states or health states related to 
cognitive impairment), respondent type and administration mode may exert a significant 
effect on questionnaire response. In such cases, samples without clear description of these 
factors should be excluded. 
 
4.3 Use of aggregate outcomes 
Most primary studies assessing utilities only report aggregate outcomes such as sample mean 
or median utilities and measures of variability for the point estimates. There is a risk of 
ecological fallacy where the nature of associations between covariates at the aggregate or 
population level is different from those at the patient or individual level [66]. For example, 
the analyst may be interested in heterogeneity in utility score by gender. However, primary 
studies often do not report gender-specific (all-male or all-female) sub-samples and only 
report aggregate utility values for gender-mixed samples. In these cases, including proportion 
of males as a covariate in meta-regression may produce a very different nature of association 
than individual-level analysis.  
 
4.4 Measure of uncertainty for utility estimates 
Synthesis of mean utilities should use the same measure of uncertainty to weight individual 
mean utilities. The most widely used weight is the inverse variance weight constructed from 
the sample standard error. Missing standard errors can be imputed based on sample 
characteristics using information from comparable samples within other primary studies that 
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do report standard errors [53]. A cruder method is to assign the average of standard errors for 
comparable samples [47]. In some cases, the standard deviation is reported but sample size is 
missing. Here a crude method is to assign a sample size of one, or if the utility estimate was 
derived through expert opinion, the number of experts could be used for the sample size.  
 
4.5 Use of median utilities 
 
Median utilities and their interquartile ranges are in themselves informative central point 
estimates and measures of variability. These statistics should therefore be extracted from 
primary studies alongside means, standard errors and ranges. Additional considerations are 
required, however, before median values are synthesised with mean values. Motivation for 
this may be to form an adequate sample size and prevent loss of information [22, 50, 55]. 
Previous meta-analyses have justified this in various ways. Sturza inspected the skewness of 
the interquartile range, and because skewness was small, median utilities were treated as 
means, and the average of sample variances reported by other samples was used as weights 
for the medians [50]. Peasgood and colleagues mapped median utilities onto mean values 
according to an estimated association between median and mean utilities reported by the 
same study [22].  
 
4.6 Synthesis of longitudinal utility estimates 
 
Primary studies reporting health state utility values can be derived using various study 
designs, including cross-sectional observational studies, longitudinal observational studies 
and prospective randomised trials. The latter two designs can generate information on 
longitudinal trajectory of utility estimates. For example, Han and colleagues assess utilities 
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for two sample of adolescents admitted to intensive care for injuries of various types (one 
sample had post-injury depression and the other did not) using the Quality of Well-Being 
(QWB) measure at 3-month, 6-month, 12-month, 18-month and 24-month follow-up points 
[67]. The analyst could conceivably utilise all ten utility estimates by, for example, including 
follow-up time as a covariate in a meta-regression model. However, this approach ignores the 
correlation of utility estimates across time [53], which will not be completely captured by 
within-study clustering within hierarchical linear models. Moreover, the time-utility 
relationship is unlikely to be linear [54]. Therefore, as far as possible, analysts should avoid 
synthesising utility estimates across different time points. Peasgood and colleagues address 
this in their analysis by conducting separate syntheses of utilities for osteoporosis-related 
fractures by category of time since fracture [49].  
 
4.7 Intervention effects on utility estimates 
 
Closely associated with longitudinal measurement of utility values is the comparison of pre- 
and post-intervention utility estimates in longitudinal observational and experimental primary 
studies. For example, in a randomised controlled trial investigating the cost-effectiveness of a 
combined physical exercise and psychosocial training intervention for paediatric cancer 
survivors, Braam and colleagues assess utilities of participants in both intervention and 
control groups using the EQ-5D-Youth (EQ-5D-Y) measure at pre-treatment baseline and 12-
month follow-up points [68]. Post-treatment utility estimates offer important information on 
treatment effects that last for a period of time and have health-related quality-of-life 
implications. However, analysts should be cautious about synthesising utility estimates across 
treatment status and then including treatment as a covariate in a meta-regression model, as 
has been done in many previous analyses (e.g. [52, 54]). First, it may be difficult to 
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disentangle between treatment effects and age-related changes in utility over time. Second, 
any estimate of treatment effect using aggregate outcomes would differ from individual-level 
estimates [47]. Moreover, endogeneity may be more acute when aggregate outcomes across 
multiple studies are used, since health status and choice of treatment modality may be closely 
correlated [48]. 
     Therefore, as far as possible, analysts should refrain from synthesising utilities with 
heterogeneous treatment status and post-treatment time profiles, although this can be difficult 
if primary studies do not offer adequate information, especially for chronic disease health 
states. In the context of a longitudinal experimental study, such as that by Braam and 
colleagues [68], analysts could treat baseline utilities from both intervention and control 
groups as estimates of utility for paediatric cancer survivors not confounded by any post-
cancer treatment. These utilities could potentially be synthesised with comparable utilities for 
paediatric cancer survivors from other studies similarly not confounded by any further 
treatment. The difference in mean utilities at the 12-month follow-up between the treatment 
and control groups within the study by Braam and colleagues could serve as an estimate of 
intervention effect. If there are other studies investigating the health utility effects of the same 
intervention, the treatment effects could be synthesised and the resulting estimate could be 
used to inform parameter values for an intervention-related state within a decision model.  
 
4.8 Model validity 
 
Many studies conducting meta-regression find it desirable to test the fit of their models. The 
𝑅2 value has been used [20], as has been Akaike’s information criterion [16], in an analogous 
way to the use of 𝐼2 and 𝜒2 statistics for fixed-effect and random-effects meta-analysis. Some 
studies have plotted predicted values against observed values [20]. Another measure of fit is 
24 
 
the proportion of predicted values above 1.0 [27]. The use of a generalised linear model with 
non-identity link (e.g., logit link) is a way of setting a bound for utility to the 0-1 range [47, 
20]. However, this makes interpretation of coefficients difficult [20], whilst some research 
suggests that non-liner models may not produce better fit than linear models [47, 69].  
 
5. Conclusion 
 
Economic analysts are likely to increasingly rely on systematic reviews and meta-analyses of 
health state utility values to inform the parameter inputs of decision-analytic modelling based 
economic evaluations. Beyond the context of economic evaluation, evidence from systematic 
reviews and meta-analyses of health state utility values can be used to inform broader health 
policy decisions. This paper provides practical guidance on how to conduct a systematic 
review and meta-analysis of health state utility values. The paper outlines a number of stages 
in conducting a systematic review of health state utility values. It further describes three 
broad approaches that have been employed in the literature to synthesise multiple estimates 
of health utilities for a given health state or condition, namely fixed-effect meta-analysis, 
random-effects meta-analysis, and mixed-effects meta-regression. Each approach is 
illustrated by a synthesis of utility values for a hypothetical decision problem, and software 
code is provided. The paper highlights a number of methodological issues pertinent to the 
conduct of meta-analysis or meta-regression. Approaches for addressing methodological 
challenges are presented and issues of methodological debate are highlighted. 
     Avenues for further research clearly arise from the material in this guidance document. 
The main evidence gap is in identifying a preferred approach for pooling health state utility 
values collected across a number of studies and generating estimates of uncertainty 
surrounding those values. The available approaches may best be viewed as complements 
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rather than competing alternatives. Selection of one approach should be informed by a 
combination of clinical and statistical judgment, and an assessment of the use to which the 
outputs will be put. Bayesian methods are increasingly being recommended by HTA agencies 
for use in meta-analysis of treatment effects, because they align well with decision modelling 
analyses, and provide additional benefits when constructing multi-level models [70]. 
However their use in the context of utility value synthesis is sparse, and further research to 
explore the value of Bayesian meta-analytic methods in this setting is clearly required. 
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Table 1. STATA and R codes for fixed-effect and random-effects meta-analysis and 
mixed-effects meta regression 
 
Code Note 
STATA 
ssc install metan (https://www.stata.com/support/faqs/statistics/meta-analysis/) 
STATA fixed-effect meta-analysis 
metan huimean se, by(yearpub) lcols(ref) xlabel(-
0.3,1) 
“huimean”: mean HUI2 and HUI3 utilities 
“se”: standard error of mean utilities 
“yearpub”: year of publication, binary variable  
“ref”: study reference 
STATA random-effects meta-analysis 
metan huimean se, random by(huicat) lcols(ref) 
xlabel(-0.3,1) second(fixed) rfdist 
“random”: specifies random-effects  
“huicat”: HUI3 vs. HUI2, binary variable 
“second(fixed)”: run fixed-effect analysis for 
comparison 
“rfdist”: prediction interval is given for the random-
effects estimate 
STATA mixed-effects meta-regression 
xtmixed huimean huicat restype admin yearpub 
[pw=inversese], || ref:, pweight(refwgt) 
“restype”: respondent type, binary variable 
“admin”: administration mode, binary variable 
“[pw=inversese]”: specifies variable “inversese”, the 
inverse of sample standard error, as weights for mean 
utilities 
“|| ref:”: treats study reference as higher level under 
which mean utilities are clustered 
“pweight(refwgt)”: weights references by variable 
“refwgt” which could be sum of sample standard 
errors 
R 
install.packages(“metafor”) (https://cran.r-project.org/web/packages/metafor/index.html) 
library(metafor) 
R fixed-effect meta-analysis 
fixed <- rma(yi=huimean, cei=se, data=meta, 
method=’FE’, subset=(yearpub>2000) 
 
 
forest(fixed, slab=paste(meta$ref)) 
“data=meta”: assumes that data is already in R format 
“method=’FE’”: specifies fixed effect option 
“subset=()”: specifies subgroup for analysis 
 
“forest()”: draws the forest plot 
R random-effects meta-analysis 
random <- rma(yi=huimean, cei=se, data=meta) 
 
predict(random) 
 
 
“predict()”: gives predicted estimate and prediction 
interval 
R mixed-effects meta-regression 
install.packages(“lme4”) 
library(lme4) 
mixed <- lmer(utilmean ~ 
valcode+rescode+modecode+yearpub + 
(1|ref),data=meta, weights=(meta$utilse), 
REML=TRUE) 
summary(mixed) 
 
 
To our knowledge, LME4 package does not allow 
weights for both level 1 and level 2 variables. Hence 
mean utility is weighted but study is not. 
“REML=TRUE” specifies restricted maximum 
likelihood estimation technique which produces 
unbiased coefficient estimates 
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Table 2. Previous systematic reviews and meta-analyses of health utility values 
Reference Health State/ 
Condition 
Review 
Period 
Statistical 
Model 
Sample Size  Dependent 
Variable 
Pooling Sub-
Groups/Covariates 
Cheng and 
Niparko (1999) 
[44] 
Profound 
deafness and 
cochlear implant 
in adults 
 
January 1966 
to May 1999 
Fixed-effect 
meta-analysis 
models 
(i) 7 mean utility 
gains from 6 
studies 
(ii) 9 mean 
utility losses 
from 5 studies 
 
For all models: 
mean utility 
gain/loss from 
HUI, VAS and 
QWB weighted by 
inverse of sample 
variance  
(i) Pooling of mean utility 
gains from cochlear implant 
(ii) Pooling of mean utility 
losses from profound 
deafness 
Post et al. 
(2001) [45] 
Stroke Inception to 
2000 
Fixed-effect 
meta-analysis 
models 
43 mean utilities 
from 23 studies 
(i) Normalised 
mean utility from 
TTO, SG, VAS, 
HUI and EQ-5D 
weighted by 
sample size 
(ii) Mean utility 
from EQ-5D scored 
by authors 
(i) Pooling by respondent 
type (healthy population, 
patients at risk for stroke, 
stroke survivors), valuation 
method and stroke severity 
(minor, major, unspecified) 
(ii) Pooling by stroke 
severity for EQ-5D only 
Tengs and Lin 
(2002) [21] 
HIV/AIDS 1985 to 2000  Mixed-effects 
meta-
regression 
model (HLM) 
74 mean/median 
utilities from 25 
studies 
 
Mean/median 
utility from SG, 
TTO, QWB, VAS, 
and expert 
judgement. Studies 
weighted by 
Disease stage (asymptomatic 
HIV, symptomatic HIV, 
AIDS); Valuation method; 
Respondent type; Lower 
bound of scale; Upper bound 
of scale; Year of publication 
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number of 
respondents 
Tengs and Lin 
(2003) [46] 
Stroke 
 
1985 to 2000 Mixed-effects 
meta-
regression 
model (HLM) 
53 mean utilities 
from 20 studies 
Mean utility from 
VAS, TTO, SG, 
and expert 
judgement 
weighted by 
sample size  
Stroke severity (minor, 
moderate, major); Valuation 
method; Respondent type; 
Upper/lower bound of scale 
Bremner et al. 
(2007) [47] 
Prostate cancer  
 
1966 to 
September 
2004 
(i) Fixed-effect 
meta-analysis 
models  
(ii) Mixed-
effects meta-
regression 
models (HLM) 
 
173 mean 
utilities from 23 
studies 
 
Mean utility from 
TTO, SG/HUI, 
VAS/QWB, and 
expert judgement 
weighted by 
product of sample 
size and inverse of 
sample variance 
(i) Fixed-effect model: 
Pooling by cancer symptom 
and severity or by source 
(respondent type and 
valuation of hypothetical 
scenarios) and valuation 
method 
(ii) HLM: Cancer stage 
(metastatic, nonmetastatic, 
mixed); Cancer symptom; 
Cancer severity; Source; 
Valuation method; Upper 
bound of scale; Study design 
(CDA vs. utility assessment); 
Administration mode 
Liem et al 
(2008) [48] 
End-stage renal 
disease; renal 
replacement 
therapy 
Inception to 
September 
2006 
Random-
effects meta-
analysis 
models 
62 mean utilities 
from 27 studies 
Mean utilities 
pooled separately 
for VAS, TTO, SG, 
EQ-5D and HUI  
Pooling by valuation method 
and treatment modality 
(peritoneal dialysis, 
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hemodialysis, kidney 
transplant) 
McLernon et al. 
(2008) [16] 
Chronic liver 
disease 
1966 to 
September 
2006 
Mixed-effects 
meta-
regression 
model (HLM) 
40 mean utilities 
from 6 studies 
(restricted to 
disease states 
with at least 3 
samples) 
Mean utility from 
EQ-5D, VAS, SG 
mapped from VAS, 
TTO, SG, HUI2 
and HUI3 weighted 
by inverse of 
sample variance 
Hepatitis C disease statesa; 
Valuation method 
Peasgood et al. 
(2009) [49] 
Osteoporosis 
related 
conditions 
January 2000 
to July 2007 
Fixed-effect 
meta-analysis 
models 
Mean utilities 
from 27 studies 
Mean utility from 
EQ-5D weighted 
by inverse of 
sample variance or 
by sample size 
Pooling of EQ-5D index 
utilities only by 
osteoporosis-related 
fractures (pre-fracture, 
vertebral, hip, wrist, 
shoulder, multiple) and year 
since fracture 
Doth et al. 
(2010) [17] 
Neuropathic 
pain  
 
Inception to 
April 2008 
(i) Random-
effects meta-
analysis 
models  
(ii) Mixed-
effects meta-
regression 
model (HLM) 
  
(i) 22 mean 
utilities from 13 
studies 
(ii) Mean 
utilities (number 
not stated) from 
10 studies  
(i) Mean utility 
from EQ-5D only 
weighted by 
inverse of sample 
variance 
(ii) Mean utility 
from EQ-5D, SG, 
15D, Global Rating 
of Health Care 
(weights not stated) 
(i) Random-effects models: 
Pooling by six neuropathic 
pain conditionsb 
(ii) HLM: Neuropathic pain 
conditions; Mean age; Sex; 
Pain duration; Pain severity; 
Comorbidities; Valuation 
method 
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Peasgood et al. 
(2010) [22] 
Breast cancer  
 
Inception to 
March 2009 
Meta-
regression 
using simple, 
pooled OLS 
models with 
standard errors 
robust to 
within-study 
clustering for:  
(i) Early breast 
cancer (EBC)  
(ii) Metastatic 
breast cancer 
(MBC) 
(i) EBC models: 
Up to 230 mean 
utilities from 29 
studiesc  
(ii) MBC 
models: Up to 
117 mean 
utilities from 20 
studiesd 
 
(i) EBC models: 
Mean utility from 
SG, VAS (worst-
best, dead-full) 
EQ-5D, TTO (top 
bound full health, 
not full health, 
other), and HUI3 
(ii) MBC models: 
Mean utility from 
VAS (worst-best, 
dead-full, rescaled 
to dead-full), EQ-
5D, and TTO (top 
bound full health, 
not full health)  
For both (i) and 
(ii): Separate model 
excluding VAS and 
TTO without full 
health top bound; 
Weighted by 
inverse of standard 
deviation or sample 
size 
(i) EBC models: Surgery 
type; Nonsurgical treatment 
type; Time since diagnosis or 
treatment; Valuation method; 
Respondent type; 
Hypothetical scenario 
valuation.  
(ii) MBC models: Treatment 
type; Response to treatment; 
Side-effects; Valuation 
method; Respondent type; 
Hypothetical scenario 
valuation 
Sturza (2010) 
[50] 
Lung cancer 
 
Not stated Mixed-effects 
meta-
223 
mean/median 
Meane utility from 
SG, VAS, HALex, 
AQoL, EQ-5D, 
Valuation method; 
Respondent type; Lung 
cancer severity; Lung cancer 
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regression 
model (HLM) 
utilities from 23 
studies 
TTO, and Expert 
judgement 
weighted by 
inverse of sample 
variance 
(sensitivity analysis 
without weights) 
type (metastatic, non-
metastatic, mixed/not 
stated); Lower bound of 
scale; Upper bound of scale; 
Year 2005 in sensitivity 
analysis 
Lung et al 
(2011) [51] 
Diabetes and 
diabetes-related 
complications  
Inception to 
end of 2009 
(i) Random-
effects meta-
analysis 
models 
(ii) Mixed-
effects meta-
regression 
model (HLM) 
(i) Random-
effects models: 
66 mean utilities 
from 45 studies 
(ii) HLM: 59 
mean utilities 
from 40 studies 
Mean utility from 
EQ-5D, TTO, SG, 
HUI2, HUI3, and 
SF-6D weighted by 
inverse of sample 
variance 
(i) Random-effects models: 
Pooling across all diabetes 
conditions and separately by 
seven diabetes-related 
complications 
(ii) HLM: Total number of 
respondents; Sample mean 
age; Proportion of males in 
sample; Valuation method 
Wyld et al. 
(2012) [52] 
Chronic kidney 
disease  
 
Inception to 
2009 
Mixed-effects 
meta-
regression 
models (HLM) 
For all models: 
326 mean 
utilities from 
190 studies 
Mean utility from 
TTO, SG, AQoL, 
EQ-5D, SF-6D, 
15D, HUI2/3, and 
EQ-5D mapped 
from SF-36 and 
SF-12 
 
HLMs: (a) Treatment type 
(pre-dialysis, dialysis, kidney 
transplant, or non-dialytic 
therapy); Valuation method 
(b) Haemodialysis vs. 
Peritoneal dialysis; 
Valuation method 
(c) Automated vs. 
ambulatory peritoneal 
dialysis; Valuation method 
(d) Proportion of sample 
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diabetic; Treatment 
modality; Valuation method 
(e) Year of publication; 
Valuation method 
Djalalov et al. 
(2014) [20] 
Colorectal 
cancer  
 
January 1980 
to January 
2013 
Mixed-effects 
meta-
regression 
models (HLM) 
with Bayesian 
priors for 
coefficients, 
intercept, 
random effects 
and error term 
(i) Baseline 
HLMs: 157 
mean utilities 
from 26 studies 
(ii) 
Supplemental 
HLMf: 351 
mean utilities 
from 26 studies 
For all models: 
Mean utility from 
TTO, SG, VAS, 
EQ-5D, and HUI3 
weighted by 
inverse of sample 
variance. Studies 
weighted by 
inverse of the sum 
of sample 
variances. 
For all models: Cancer site 
(colorectal, colon, rectal); 
Cancer stage; Time to or 
from initial care; Valuation 
method; Administration 
mode 
Mohiuddin and 
Payne (2014) 
[19] 
Unipolar 
depression in 
adults without 
significant 
comorbidity  
 
1946 to 2012 Random-
effects meta-
analysis 
models using 
Bayesian 
uninformative 
prior for 
between-study 
variance 
18 mean utilities 
from 6 studiesg  
 
Mean utility from 
SG or EQ-5D 
weighted by 
inverse of sample 
variance 
Pooling by depression 
severity (mild, moderate, 
severe) and valuation 
method (SG, EQ-5D)  
 
Si et al. (2014) 
[53] 
Osteoporosis 
related 
conditions 
Inception to 
2013 
(i) Random-
effects meta-
analysis 
models 
362 mean 
utilities from 62 
studies: 106 
mean utilities 
Mean utility from 
EQ-5D, HUI, 
QWB, SF-6D, RS, 
VAS, SG, and TTO 
(i) Random-effects models: 
Pooling by osteoporosis-
related condition 
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(ii) Univariate 
mixed-effects 
meta-
regression 
models (HLM) 
(iii) 
Multivariate 
HLMs 
for pre-fracture, 
89 for hip 
fracture, 130 for 
vertebral 
fracture, and 37 
for wrist fracture 
weighted by 
inverse of sample 
variance  
(ii) For each osteoporosis-
related condition, separate 
univariate HLM for: Time 
since fracture; Age group; 
Valuation method; 
Retrospective assessment; 
Country; Sex; Fracture 
history 
(iii) Multivariate HLM for 
each osteoporosis-related 
condition: Time since 
fracture; Age; Valuation 
method; Retrospective 
assessment; Sex; Fracture 
history   
Tran et al. 
(2015) [54] 
HIV/AIDS  2000 to 
February 
2014 
(i) Mixed-
effects meta-
regression 
models (HLM) 
for cross-
sectional data  
(ii) 1st and 2nd 
order 
fractional 
polynomial 
regression 
models (FPR) 
for 
(i) HLM: 218 
mean utilities 
from 49 studies 
(ii) FPR: 99 
mean utilities 
from 14 studies  
For all models: 
Mean utility from 
EQ-5D, HUI2/3, 
SF-6D, 15D, SG, 
TTO, and VAS 
(i) HLM: Valuation method; 
Disease stage (asymptomatic 
HIV, symptomatic HIV, 
AIDS); Treatment type; 
Country setting (developed 
vs. developing); Year of 
publication 
(ii) FPR: Valuation method; 
Length of ART; Country 
setting; Year of publication 
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longitudinal 
change in 
utility over 
duration of 
ART  
Sampson et al. 
(2016) [55] 
Diabetic 
retinopathy and 
maculopathy  
Inception to 
2015 
(i) Fixed-effect 
meta-analysis 
models  
(ii) Univariate 
mixed-effects 
meta-
regression 
models (HLM) 
(iii) 
Multivariate 
HLM  
For all models: 
317 
mean/median 
utilities from 41 
studies. Assume 
that median 
utilities are 
normally 
distributed and 
treat as mean 
values, using 
IQR to estimate 
standard error 
(i) Fixed-effect 
models: EQ-5D, 
EQ-5D VAS, 
HUI3, 15D, SF-6D, 
SG, and TTO 
(ii-iii) For HLMs: 
EQ-5D, EQ-5D 
VAS, HUI3, 15D, 
SF-6D, SG, TTO, 
QWB, and VAS. 
Mean utilities 
weighted by 
product of sample 
size and inverse of 
sample variance 
(i) Fixed-effect models: 
Pooling by retinopathy and 
maculopathy (R0M0) grades 
and valuation method 
(ii) Univariate HLMs: R0M0 
grades; Valuation method; 
Year of publication; Study 
design; Diabetes type; Tariff 
population; Respondent type, 
Cooper quality score; 
Administration mode 
(iii) Multivariate HLM: 
R0M0 grades; Valuation 
method; Tariff population; 
Respondent type 
Kwon et al. 
(2017) [27] 
Childhood 
health 
conditions or 
states  
Inception to 
December 
2015 
(i) Fixed-effect 
meta-analysis 
models 
(ii) Mixed-
effects meta-
(i) Fixed-effect 
models: 1,073 
mean utilities 
from 272 studies 
(ii) HLMs: (a) 
279 mean 
utilities from 89 
(i) Fixed-effect 
models: Mean 
utility from all 
direct and indirect 
valuation methods 
used in childhood 
populationh 
weighted by 
(i) Fixed-effect models: 
Pooling by ICD-10 
delineated health condition 
categories and valuation 
method  
(ii) HLMs: ICD-10 
delineated health condition 
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regression 
models (HLM)  
studies; (b) 211 
mean utilities 
from 67 studies 
inverse of sample 
variance 
(ii) HLMs: Mean 
utility from (a) 
HUI3 and (b) VAS 
weighted by 
inverse of standard 
error. Studies 
weighted by 
number of 
respondents 
categories; Valuation of 
hypothetical scenarios; 
Respondent type; 
Administration mode; 
Minimum age of sample; 
Country (developed vs. 
developing) 
 FE: Fixed-effect; RE: Random-effects; ME: Mixed-effects; HLM: Hierarchical linear model; SG: Standard gamble; CG: Chained gamble; 
TTO: Time trade-off; QWB: Quality of well-being scale; VAS: Visual analogue scale; RS: Rating scale; HALex: Health activities and 
limitations index; AQoL: Assessment of quality of life; ART: Anti-retroviral therapy 
a Moderate hepatitis C, compensated cirrhosis, decompensated cirrhosis, and post-liver transplant 
b   Diabetic retinopathy, failed back surgery syndrome, post-herpetic neuralgia, phantom/residual limb pain, central neuropathy, and mixed 
neuropathy 
c Sample size depended on weights used and valuation methods included: 230 mean utilities from 29 studies when utilities weighted by 
sample size; 163 mean utilities from studies reporting standard deviation when utilities weighted by inverse of standard deviation; and 145 
mean utilities when utilities weighted by sample size and VAS and TTO without full health top bound excluded. 
d Sample size depended on weights used and valuation methods included: 117 mean utilities from 20 studies when utilities weighted by 
sample size; 77 mean utilities from studies reporting standard deviation when utilities weighted by inverse of standard deviation; and 86 
mean utilities when utilities weighted by sample size and VAS and TTO without full health top bound excluded. 
e Median utilities given minimal skew in distribution; median utilities weighted by pooled sample variance.  
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f Samples within a study which were identical with respect to covariates included in regression but heterogeneous with respect to other 
variables were aggregated in baseline models but disaggregated in supplemental model. 
g 9 mean utilities from 3 studies using SG and 9 utilities from 3 studies using EQ-5D; 3 mean utilities per depression severity (mild, 
moderate, severe) for both SG and EQ-5D. 
h VAS, EQ-5D VAS, EQ-5D-Y VAS, TTO, SG, CG, QWB, 15D, 16D, 17D, EQ-5D, EQ-5D-Y, AQoL-5D, AQoL-6D, CHU9D, HUI2, 
HUI3, SF-6D, PAHOM and non-preference-based measures mapped to QALY 
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Table 3. Mixed-effect meta-regression by hierarchical linear model of utility values for 
paediatric cancer survivors measured by HUI2 and HUI3; 22 samples across 7 studies  
Variable 
Coefficient 
(SE) 
Coefficient 
95% CI P-value 
Constant (Utility for paediatric cancer survivors 
measured by HUI3 after 2000; self-response; self-
administered questionnaire) 
0.870 
(0.043) 
0.786 to 0.953 <0.001 
Methodological factors    
Valuation method: Reference HUI3 vs. 
HUI2 
0.043 
(0.024) 
-0.003 to 0.090 0.068 
Respondent type: Reference self-response 
vs. proxy-response 
0.029 
(0.034) 
-0.037 to 0.095 0.387 
Administration mode: Reference self-
administered vs. interview-administered 
-0.042 
(0.009) 
-0.060 to -0.025 <0.001 
Year of publication: Reference after 2000 
vs. before or in 2000 
-0.115 
(0.040) 
-0.194 to -0.036 0.004 
Average predicted utility from model, 
weighted by inverse prediction standard error 
0.937 
(0.016) 
0.905 to 0.969  
 
  
47 
 
Figure 1. Fixed-effect meta-analysis of utility values for childhood cancer survivors assessed 
using Health Utilities Index 2 (HUI2) and Health Utilities Index 3 (HUI3) 
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Figure 2. Random-effects and fixed-effect meta-analysis for childhood cancer survivors 
assessed using HUI2 and HUI3 
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Appendix A: Search strategy adopted by systematic review of childhood health state 
utility values 
Database: PubMed, Embase, Web of Science, PsycINFO, EconLit, CINAHL, Cochrane 
Library 
Date: 26.01.2016 
Include articles with publication date up to 31.12.2015 
Limit search to title and abstract 
Search 
Category 
 Search Terms 
Utility Terms 1 Utilit* or disutilit* or HSUV  
2 “quality adjusted life year*” or QALY or “quality-adjusted life 
year*” or “quality-adjusted life-year*”  
3 OR (1 to 2) 
Indirect 
Valuation 
Method Terms 
4 EQ-5D or “EQ 5D” or EQ5D or Euroqol or “Euro qol” or EQ-5D-
Y or "EQ 5D Y" 
5 Short-form survey-6D or short form 6D or SF-6D or “SF 6D” or 
SF6D 
6 “health utilities index” or HUI 
7 “quality of well being” or “quality of well-being” or QWB 
8 16D Health-Related Quality of Life or 16D HRQoL or 17D 
Health-Related Quality of Life or 17D HRQoL 
9 AQoL-6D or Assessment of Quality of Life-6D  
10 “Child Health Utility 9 Dimension” or CHU9D or CHU-9D or 
“CHU 9D” 
11 Adolescent Health Utility Measure or AHUM 
12 15-dimensional instrument or 15 dimensional instrument or 15D 
13 preference-based measure of HRQoL or preference based measure 
of HRQoL 
14 multi-attribute utility instrument or multiattribute utility 
instrument 
15 OR (4 to 14) 
Direct 
Valuation 
Method Terms  
16 Standard Gamble or standard-gamble 
17 Time trade off or time trade-off 
19 best worst scaling or best-worst scaling 
19 Discrete choice experiment or discrete-choice experiment 
20 person trade off or person trade-off 
21 scoring algorithm or scoring-algorithm 
22 utility elicitation or direct elicitation 
23 OR (16 to 22) 
24 3 OR 15 OR 23 
Childhood 
Terms 
25 Child* or adolesc* or kid or kids or youngster* or teen* or youth* 
or infant* or newborn* or perinat* or neonat* or “parent proxy” 
26 Pediatri* or paediatri* 
27 OR (25 to 26) 
Main Search 28 24 AND 27 
29 Remove non-English Title and/or Abstract 
30 Remove Duplicates Across Databases 
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Source: Kwon J, Kim SW, Ungar WJ, Tsiplova K, Madan J, Petrou S. A Systematic Review 
and Meta-Analysis of Childhood Health Utilities. Med Decis Making. 
2017:272989X17732990.[27] 
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Appendix B: Example data extraction sheet developed for systematic review of 
childhood health state utility values 
Variables Examples Response 
Reference   
Country/ 
jurisdiction/context 
Country, 
sociodemographic 
context, clinic type and 
location, etc. 
 
Health 
condition/state or 
intervention state 
Health state (specify 
duration), condition sub-
category, medical 
treatment or intervention, 
phase of care (e.g. 
survivors, undergoing 
treatment), etc. 
 
Respondent type Children, patients, 
parents, caregivers, 
nurses, physicians, other 
proxies, general 
population, etc. 
 
Age of target 
childhood group 
Age at diagnosis, age at 
study, mean, median, 
range, min, max 
 
Size of study 
population 
  
Direct valuation 
method applied (if 
applicable) 
Time trade-off, standard 
gamble, person trade-off, 
discrete choice 
experiment, etc. 
 
Indirect valuation 
method applied (if 
applicable) 
16D, 17D, AQol-6D, 
HUI2, HUI3, EQ-5D, EQ-
5D-Y, QWB, etc. 
 
Tariff if indirect 
valuation method 
applied 
UK MVH, etc.  
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Utility values Mean, median, SD, IQ 
range, min, max, utility of 
control or reference 
group, utility difference 
between groups or after 
intervention, etc. 
 
Study design Cross-sectional study, 
clinical trial, longitudinal 
prospective, internet 
survey, etc. 
 
Response quality Response rate, 
information on dropouts, 
reasons for loss to follow-
up, etc. 
 
Statistical method Mean values, Linear 
multivariate regression 
model, etc. 
 
Study caveats and 
conclusion 
Condition associated with 
lower utility; concern over 
sample size; concern over 
construct validity of 
instrument; etc. 
 
Quality 
appraisal:  
Study design: Definition of 
study group: 
Representative 
study group: 
Other issues: 
Comment: 
Source: Kwon J, Kim SW, Ungar WJ, Tsiplova K, Madan J, Petrou S. A Systematic Review 
and Meta-Analysis of Childhood Health Utilities. Med Decis Making. 
2017:272989X17732990.[27] 
 
